Literature DB >> 30885383

Clozapine prescription pattern in patients with schizophrenia in Asia: The REAP survey (2016).

Shi-Wei Xu1, Min Dong2, Qinge Zhang3, Shu-Yu Yang4, Lian-Yu Chen5, Kang Sim6, Yan-Ling He7, Helen Fk Chiu8, Norman Sartorius9, Chay-Hoon Tan10, Mian-Yoon Chong11, Naotaka Shinfuku12, Shih-Ku Lin13, Chee H Ng14, Gabor S Ungvari15, Eunice Najoan16, Roy Abraham Kallivayalil17, Ruzita Jamaluddin18, Afzal Javed19, Hitoshi Iida20, Thiha Swe21, Bin Zhang22, Yu-Tao Xiang23.   

Abstract

Clozapine is an effective antipsychotic medication for treatment resistant schizophrenia and is widely used in Asian countries. This study investigated clozapine prescription patterns and their associated factors in Asian countries and territories based on the database of the Research on Asian Psychotropic prescription study (REAP) conducted in 2016. Demographic and clinical information of 3744 schizophrenia patients in 15 Asian countries and territories was collected with a standardized data collection form. In total, 18.4% of the sample received clozapine, ranging from 2.6% in Japan to 32.3% in Hong Kong. Binary logistic regression analysis revealed that higher antipsychotic dose (OR = 1.002, P < 0.001), less frequent first admission in the sample (OR = 0.6, P < 0.001), more severe negative symptoms (OR = 1.4, P = 0.001) and less first generation antipsychotics (FGAs) (OR = 0.2, P < 0.001) were independently and significantly associated with clozapine prescription. Clozapine is frequently and increasingly prescribed for schizophrenia in Asia, with large variation across countries and territories. Given the diverse prescription patterns of clozapine found in Asian countries/territories, the clinical rationale of clozapine prescription needs careful consideration in Asia with more local input.
Copyright © 2019 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Asia; Clozapine; Prescription patterns; Schizophrenia

Year:  2019        PMID: 30885383     DOI: 10.1016/j.psychres.2019.02.056

Source DB:  PubMed          Journal:  Psychiatry Res        ISSN: 0165-1781            Impact factor:   3.222


  7 in total

1.  Pro-inflammatory cytokine levels are elevated in female patients with schizophrenia treated with clozapine.

Authors:  Xiaoping Yuan; Song Wang; Yudong Shi; Yating Yang; Yulong Zhang; Lei Xia; Kai Zhang; Huanzhong Liu
Journal:  Psychopharmacology (Berl)       Date:  2022-01-26       Impact factor: 4.530

2.  A Comprehensive Monitoring of Clozapine and Related Components in Clinical Practices. Saudi Arabian Scenario.

Authors:  Jisha M Lucca; Fatima M Al-Turaifi; Al-Mubayedh Safyah; Feras A Hamad Al-Awad
Journal:  Psychopharmacol Bull       Date:  2021-11-03

3.  Caffeine-clozapine interaction associated with severe toxicity and multiorgan system failure: a case report.

Authors:  Alex Yartsev; Carmelle Peisah
Journal:  BMC Psychiatry       Date:  2021-04-13       Impact factor: 3.630

Review 4.  Recent Discussions on Dopamine Supersensitivity Psychosis: Eight Points to Consider When Diagnosing Treatment-Resistant Schizophrenia.

Authors:  Nobuhisa Kanahara; Hiroshi Kimura; Yasunori Oda; Fumiaki Ito; Masaomi Iyo
Journal:  Curr Neuropharmacol       Date:  2021       Impact factor: 7.708

5.  Clozapine prescribing practice and trends in Qatar: First national observational study.

Authors:  Ovais Wadoo; Javed Latoo; Majid Alabdulla; Yassin Eltorki; Sadaf Riaz; Mustafa Abdul Karim; Mohammed Abu-Hafizah; Shuja Reagu
Journal:  Brain Behav       Date:  2022-06-01       Impact factor: 3.405

6.  Worldwide antipsychotic drug search intensities: pharmacoepidemological estimations based on Google Trends data.

Authors:  Richard Ågren
Journal:  Sci Rep       Date:  2021-06-23       Impact factor: 4.379

Review 7.  A Rational Use of Clozapine Based on Adverse Drug Reactions, Pharmacokinetics, and Clinical Pharmacopsychology.

Authors:  Jose de Leon; Can-Jun Ruan; Georgios Schoretsanitis; Carlos De Las Cuevas
Journal:  Psychother Psychosom       Date:  2020-04-14       Impact factor: 17.659

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.